BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, December 16, 2025
Home » Topics » Disease categories and therapies » Substance use and poisoning

Substance use and poisoning
Substance use and poisoning RSS Feed RSS

Resilient develops wearable device to reverse opioid overdoses

March 16, 2023
By Annette Boyle
Free, no-prescription-required access to naloxone injectors and nasal sprays has reduced deaths from opioid overdoses by 11% in some communities, but they only work if someone with the reversal agent is available when a person overdoses. Many times, unfortunately, opioid users are alone when an overdose occurs. Resilient Lifescience Inc. hopes to save those lives, too. The company is developing a wearable patch that monitors vital signs and automatically administers naloxone when needed.
Read More
Concept image for radiation syndrome
Substance Use & Poisoning

RNCP selects Redhill's opaganib for evaluation for acute radiation syndrome

March 1, 2023
Redhill Biopharma Ltd.'s opaganib hydrochloride (ABC-294640) has been selected by the Radiation and Nuclear Countermeasures Program (RNCP), of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the nuclear medical countermeasures product development pipeline as a potential treatment for acute radiation syndrome (ARS).
Read More
Gloved hand holding powder substance in bag
Substance Use & Poisoning

CSX-1004 blocks fentanyl-induced respiratory depression in nonhuman primates

March 1, 2023
Cessation Therapeutics Inc. has announced outcomes of a new study demonstrating that its anti-fentanyl monoclonal antibody treatment, CSX-1004, may provide robust and durable protection from life-threatening respiratory depression caused by high doses of fentanyl. The findings come from the company’s ongoing series of proof-of-concept studies in nonhuman primates.
Read More
Substance Use & Poisoning

Aphiotx describes new PANX1 inhibitors for opioid withdrawal

Feb. 9, 2023
Aphiotx Inc. has identified sulfamoyl benzene derivatives acting as pannexin-1 (PANX1; MRS1) inhibitors reported to be useful for the treatment of opioid withdrawal.
Read More
Illustration of pill being analyzed
Substance Use and Poisoning

Clearmind completes IND-enabling studies for CMND-100 for alcohol use disorder

Dec. 14, 2022
Clearmind Medicine Inc. has completed IND-enabling studies with its 5-methoxy-2-aminoindane (MEAI)-based lead compound, CMND-100, aimed at treating alcohol use disorder (AUD). The company is preparing for an IND submission early next year to the FDA and the Israeli Ministry of Health to start first-in-human phase I/IIa studies in the U.S. and Israel.
Read More
Illustration of stomach, beneficial gut bacteria.

Gut microbiota degrade intestinal nicotine, alleviate smoking-related liver disease

Oct. 25, 2022
By Mar de Miguel
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
Read More
Illustration of stomach, beneficial gut bacteria.

Gut microbiota degrade intestinal nicotine, alleviate smoking-related liver disease

Oct. 21, 2022
By Mar de Miguel
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease in smokers.
Read More
Gastrointestinal

Gut microbiota degrade intestinal nicotine, alleviate smoking-related liver disease

Oct. 19, 2022
By Mar de Miguel
Peking University researchers in collaboration with the NIH have discovered a new biochemical pathway related to a bacterium that eliminates nicotine in the intestine. The findings could lead to new ways to improve nonalcoholic fatty liver disease (NAFLD) in smokers. In addition to the lung and the brain, nicotine can accumulate in the intestine, where the bacteria Bacteroides xylanisolvens could reduce its concentration and the severity of NAFLD. In their study, published in Nature Oct. 19, 2022, the researchers described the enzymes involved in this process and a new undiscovered pathway.
Read More
Illustration of pill being analyzed
Substance use and poisoning

GATC Health compounds enter preclinical development for fentanyl addiction and opioid use disorders

Oct. 7, 2022
GATC Health Corp. has announced that the new drug candidates discovered by its proprietary artificial intelligence (AI) drug discovery and prediction platform to treat opioid use disorder (OUD) and fentanyl addiction have entered preclinical development.
Read More
Pipet, test tubes, chemical structure
Substance use and poisoning

Spironolactone shows promise for alcohol abuse disorder in rodents

Oct. 3, 2022
Recent evidence suggests that spironolactone, a mineralocorticoid receptor antagonist, may modulate alcohol seeking and consumption, for which current therapies are limited.
Read More
Previous 1 2 3 4 5 6 7 8 9 10 11 12 … 119 120 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 16, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 16, 2025.
  • Businesspeople shaking hands, meeting with cityscape, charts

    Deals and an M&A strengthen end-of-year numbers

    BioWorld
    Two large deals and an acquisition, totaling about $4.64 billion in all, are helping wrap up what’s turning out to be a strong year. Through the first 11 months...
  • Illustration of tau accumulating in a neuron cell.

    ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug

    BioWorld
    ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...
  • PET imaging

    Radiopharm Theranostics’ RAD-101 meets brain metastases endpoints

    BioWorld
    Radiopharm Theranostics Ltd.’s radiotracer RAD-101 met the primary endpoint in 92% of patients in the phase IIb imaging trial in brain metastases, according to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing